Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, including asthma and chronic obstructive pulmonary disease (COPD). The company is also involved in developing PUR0200, a reformulation of an existing long-acting antimuscarinic agent that has completed Phase Ib clinical development, which blocks the effects of acetylcholine on muscarinic receptors to reverse airway obstruction in COPD patients. It has a license agreement with RespiVert Ltd. to develop kinase inhibitor for access to a portfolio of novel drug candidates; and a partnership agreement with Vectura Group plc to develop its drug candidate. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PULM
CUSIPN/A
Phone781-357-2333
Debt
Debt-to-Equity RatioN/A
Current Ratio2.38
Quick Ratio2.38
Price-To-Earnings
Trailing P/E Ratio-0.41
Forward P/E Ratio-0.57
P/E GrowthN/A
Sales & Book Value
Annual Sales$340,000.00
Price / Sales53.83
Cash FlowN/A
Price / CashN/A
Book Value$0.48 per share
Price / Book0.81
Profitability
EPS (Most Recent Fiscal Year)($0.93)
Net Income$-18,050,000.00
Net MarginsN/A
Return on Equity-172.66%
Return on Assets-117.18%
Miscellaneous
Employees24
Outstanding Shares46,930,000
Market Cap$17.94 million
Pulmatrix (NASDAQ:PULM) Frequently Asked Questions
What is Pulmatrix's stock symbol?
Pulmatrix trades on the NASDAQ under the ticker symbol "PULM."
How were Pulmatrix's earnings last quarter?
Pulmatrix Inc (NASDAQ:PULM) issued its quarterly earnings data on Friday, August, 3rd. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.04. View Pulmatrix's Earnings History.
When is Pulmatrix's next earnings date?
What price target have analysts set for PULM?
2 brokers have issued 12-month target prices for Pulmatrix's stock. Their predictions range from $3.00 to $3.00. On average, they expect Pulmatrix's share price to reach $3.00 in the next year. This suggests a possible upside of 669.2% from the stock's current price. View Analyst Price Targets for Pulmatrix.
What is the consensus analysts' recommendation for Pulmatrix?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pulmatrix.
Who are some of Pulmatrix's key competitors?
Some companies that are related to Pulmatrix include Sunesis Pharmaceuticals (SNSS), Oncolytics Biotech (ONCY), OncoSec Medical (ONCS), Neurotrope (NTRP), Aquinox Pharmaceuticals (AQXP), Bellerophon Therapeutics (BLPH), Helix Biopharma (HBPCF), IntelGenx Technologies (IGXT), DiaMedica Therapeutics (DMCAF), Imprimis Pharmaceuticals (IMMY), Catabasis Pharmaceuticals (CATB), SCYNEXIS (SCYX), Evoke Pharma (EVOK), VIVUS (VVUS) and Versartis (VSAR).
Who are Pulmatrix's key executives?
Pulmatrix's management team includes the folowing people:
- Dr. Robert W. Clarke, CEO, Pres & Director (Age 49)
- Mr. Teofilo David Raad, Chief Bus. Officer (Age 48)
- Dr. James M. Roach, Chief Medical Officer (Age 58)
- Dr. Robert S. Langer Jr., Founder & Member of Scientific Advisory Board (Age 69)
- Prof. David A. Edwards, Founder & Member of Scientific Advisory Board (Age 57)
Has Pulmatrix been receiving favorable news coverage?
Media headlines about PULM stock have trended somewhat positive on Friday, according to Accern Sentiment Analysis. Accern scores the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pulmatrix earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Pulmatrix.
Who are Pulmatrix's major shareholders?
Which institutional investors are buying Pulmatrix stock?
How do I buy shares of Pulmatrix?
Shares of PULM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pulmatrix's stock price today?
One share of PULM stock can currently be purchased for approximately $0.39.
How big of a company is Pulmatrix?
Pulmatrix has a market capitalization of $17.94 million and generates $340,000.00 in revenue each year. The biotechnology company earns $-18,050,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis. Pulmatrix employs 24 workers across the globe.
How can I contact Pulmatrix?
Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-357-2333 or via email at [email protected]
MarketBeat Community Rating for Pulmatrix (NASDAQ PULM)
MarketBeat's community ratings are surveys of what our community members think about Pulmatrix and other stocks. Vote "Outperform" if you believe PULM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PULM will underperform the S&P 500 over the long term. You may vote once every thirty days.
